Xcellerex, Inc. and Gallus BioPharmaceuticals, LLC have entered into a collaboration to provide Gallus with expanded cGMP biomanufacturing capacity using Xcellerex’s FlexFactory GMP manufacturing platform suite. The collaboration provides Gallus with scalable manufacturing and lab technology to expand its contract manufacturing business. This partnership will also provide Xcellerex customers with access to Gallus’ commercial, FDA-approved, biomanufacturing facility in St. Louis, MO.

Under the agreement, Gallus is acquiring several Xcellerex bioproduction systems for new suites and labs at its existing manufacturing facility. Gallus is also acquiring small-scale 10L bioreactors and a FlexFactory cGMP manufacturing line with XDR single-use bioreactors as large as 2000 liter scale for clinical supply. The two companies will provide their customers with access to Gallus’ biomanufacturing expertise and facility.

“Gallus has a unique contract manufacturing business model that enables us to respond to clients’ changing capacity needs quickly, and achieve rapid, high quality production at a competitive price,” said Mark Bamforth, president and chief executive officer of Gallus. “The partnership with Xcellerex allows us to leverage their single-use biomanufacturing platform. This is a strategic investment that rapidly provides us with additional manufacturing capacity and scale-up capabilities to deliver development, clinical and commercial products and services”

Xcellerex chief executive officer Guy Broadbent, said, “Gallus is capitalizing on the extraordinary flexibility afforded by the FlexFactory, along with the extensive manufacturing experience of its team, to provide innovative solutions for established as well as development-stage biopharmaceutical companies. The agreement provides us with an important path to offer full-scale commercial manufacturing to our customers.”